sNDA submitted seeking approval of IGALMI in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports ...
Our resident prospect expert ranks his top 50 MLB prospects heading into the 2026 season.
Almirall has signed a collaboration and licensing agreement with Shanghai Huaota Biopharmaceutical, a subsidiary of Zhejiang Huahai Pharmaceutical, to develop a monoclonal antibody candidate for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results